LKLesley C. Kaye

Lesley C. Kaye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lesley C. Kaye has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy

    by Dawn Eliashiv, Vikram R. Rao, Barbara C. Jobst, Jerzy P. Szaflarski, John D. Rolston, Lesley C. Kaye, Taneeta Mindy Ganguly, Katie Bullinger, Patricia C. Dugan, David E. Burdette, et al.

    Background and ObjectivesNeuromodulation therapies are approved for the treatment of focal epilepsy based on data from randomized controlled trials (RCTs). After approval of a responsive direct bra...


  • Open Access

    Delayed and deferred surgery associated with cenobamate use in people with drug‐resistant focal epilepsy

    by Jacob Pellinen, Stefan Sillau, Aimee Bui, Alexandra Danciutiu, Lesley Kaye, Ashvin Sood, Louis Ferrari, William E. Rosenfeld, Christopher Elder

    Objective: Cenobamate has been shown to be an effective antiseizure medication for some patients with drug‐resistant focal epilepsy being considered for epilepsy surgery. This retrospective single‐center study evaluated whether surgery was obtained within 12 months for patients who received cenobamate as a treatment during the presurgical evaluation and those who did not, comparing across years before and after cenobamate approval. Methods: Patients undergoing surgical evaluation for drug‐resistant focal epilepsy at the University of Colorado during 2018 and 2023 who had 12 months of follow‐up data were analyzed. Comparison years were also chosen to avoid the confounding effect of the COVID‐19 pandemic on surgical volume (2020–2021). This allowed for comparison times before and after cenobamate's US Food and Drug Administration approval. The primary outcome (surgery within 12 months) was modeled with potential explanatory variables using multiple logistic regression. A p ‐value of <.05 was considered significant. Results: After controlling for potentially confounding clinical and demographic variables, cenobamate use during the presurgical evaluation period was associated with .13 lower odds of surgery within 12 months compared to not being prescribed this medication (95% confidence interval [CI] = .04–.42, p < .001). Being Hispanic or Latino was significantly associated with .23 lower odds of surgery within 12 months compared to patients who did not report being Hispanic or Latino (95% CI = .09–.61, p = .003). Year of evaluation (2023 vs. 2018), education level, age, and sex did not have significant associations with undergoing surgery within 12 months. Significance: Patients with drug‐resistant focal epilepsy undergoing evaluation for epilepsy surgery may benefit from cenobamate. In this study, patients who received cenobamate during the presurgical evaluation were less likely to undergo surgery within 12 months. The delay to surgery identified among Hispanic and Latino patients suggests potential barriers to care in this patient population warranting further investigation.


  • Open Access

    Aperiodic activity as a biomarker of seizures and neuromodulation

    by David Satzer, Lesley C. Kaye, Steven G. Ojemann, Daniel R. Kramer, John A. Thompson


  • Open Access

    Feasibility study of microburst VNS therapy in drug-resistant focal and generalized epilepsy

    by Cornelia Drees, Pegah Afra, Ryan Verner, Lesley Kaye, Amy Keith, Mei Jiang, Jerzy P. Szaflarski, Kathryn Nichol, Danielle McDermott, Mesha Gay Brown, et al.


  • Open Access

    Small Cell Lung Cancer Presenting as Severe Thrombocytopenia and Refractory Hypokalemia

    by Rohan Mandaliya, Lesley Hughes, Herbert Auerbach, Felice LePar

    A 70-year-old female with a history of mild cirrhosis was referred by her primary care provider for a platelet count of 36,000/μL which had dropped from 47,000/μL in a week along with mild pain in extremities. Serum potassium was low (2.9 mEq/L) in spite of the patient being recently started on potassium supplement on outpatient for hypokalemia. Initially thrombocytopenia was attributed to cirrhosis. However, platelet counts continued to drop to a nadir of 9000/μL in spite of several platelet transfusions. Hypokalemia was refractory to potassium supplements. Subsequent bone marrow biopsy revealed extensive marrow necrosis with a focus of small cell tumor cells of pulmonary origin. CT scan of the chest showed a spiculated left lung mass. The ACTH level was high, with normal rennin and aldosterone levels. The patient likely had ectopic ACTH syndrome from small cell lung cancer. She died within few days of diagnosis. Severe thrombocytopenia and refractory hypokalemia can rarely be initial presentations of small cell lung cancer. Thrombocytopenia should prompt an evaluation for bone marrow metastases and a search for undiagnosed systemic malignancy. In severe cases of metastases, bone marrow necrosis can be present. Refractory hypokalemia can be the sole presentation of ectopic ACTH production.